HRP20150530T1 - Spojevi korisni za inhibiranje chk1 - Google Patents

Spojevi korisni za inhibiranje chk1 Download PDF

Info

Publication number
HRP20150530T1
HRP20150530T1 HRP20150530TT HRP20150530T HRP20150530T1 HR P20150530 T1 HRP20150530 T1 HR P20150530T1 HR P20150530T T HRP20150530T T HR P20150530TT HR P20150530 T HRP20150530 T HR P20150530T HR P20150530 T1 HRP20150530 T1 HR P20150530T1
Authority
HR
Croatia
Prior art keywords
cancer
salt
compound
methylpyridin
pyrazin
Prior art date
Application number
HRP20150530TT
Other languages
English (en)
Croatian (hr)
Inventor
Sajan Joseph
Susanta Samajdar
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20150530T1 publication Critical patent/HRP20150530T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08Acetic acid
    • C07C53/10Salts thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/06Oxalic acid
    • C07C55/07Salts thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/10Succinic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HRP20150530TT 2010-11-08 2011-11-01 Spojevi korisni za inhibiranje chk1 HRP20150530T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41113710P 2010-11-08 2010-11-08
PCT/US2011/058692 WO2012064548A1 (en) 2010-11-08 2011-11-01 Compounds useful for inhibiting chk1
EP11788263.9A EP2638033B1 (en) 2010-11-08 2011-11-01 Compounds useful for inhibiting chk1

Publications (1)

Publication Number Publication Date
HRP20150530T1 true HRP20150530T1 (hr) 2015-06-19

Family

ID=45044707

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150530TT HRP20150530T1 (hr) 2010-11-08 2011-11-01 Spojevi korisni za inhibiranje chk1

Country Status (22)

Country Link
US (1) US9067920B2 (enExample)
EP (1) EP2638033B1 (enExample)
JP (1) JP5792316B2 (enExample)
KR (1) KR101533166B1 (enExample)
CN (1) CN103180311B (enExample)
AR (1) AR083575A1 (enExample)
AU (1) AU2011326230B2 (enExample)
BR (1) BR112013010009B1 (enExample)
CA (1) CA2816944C (enExample)
DK (1) DK2638033T3 (enExample)
EA (1) EA022096B1 (enExample)
ES (1) ES2541414T3 (enExample)
HR (1) HRP20150530T1 (enExample)
JO (1) JO3145B1 (enExample)
ME (1) ME02119B (enExample)
MX (1) MX2013005181A (enExample)
PL (1) PL2638033T3 (enExample)
PT (1) PT2638033E (enExample)
RS (1) RS54012B1 (enExample)
SI (1) SI2638033T1 (enExample)
TW (1) TWI501956B (enExample)
WO (1) WO2012064548A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
WO2017132928A1 (en) 2016-02-04 2017-08-10 Pharmaengine, Inc. 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN112457306A (zh) 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
US11564920B2 (en) 2020-11-30 2023-01-31 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1H-pyrazol-3-amine derivative
AU2021389190A1 (en) 2020-11-30 2023-06-29 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1h-pyrazol-3-amine derivative
MX2024007910A (es) 2021-12-24 2024-09-04 Sumitomo Pharma Co Ltd Derivado de 1h-pirazol-3-amina que tiene una estructura principal bicíclica.
EP4534100A1 (en) * 2022-05-27 2025-04-09 Sumitomo Pharma Co., Ltd. Therapeutic for cancer refractory to immune checkpoint inhibitor
TW202442234A (zh) * 2023-04-14 2024-11-01 美商纜圖藥品公司 Cdk2抑制劑

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0412820A (pt) * 2003-07-25 2006-09-26 Pfizer compostos de aminopirazol e utilização como inibidores de chk1
DE602004031777D1 (en) * 2004-01-05 2011-04-21 Astrazeneca Ab Thiophenderivate als chk-1-inhibitoren
ATE415397T1 (de) * 2004-06-04 2008-12-15 Arena Pharm Inc Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
US20080194606A1 (en) * 2005-05-05 2008-08-14 Astrazeneca Pyrazolyl-Amino-Substituted Pyrimidines and Their Use in the Treatment of Cancer
JP2008543754A (ja) * 2005-06-09 2008-12-04 メルク エンド カムパニー インコーポレーテッド チェックポイントキナーゼの阻害剤
WO2008117050A1 (en) * 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
PA8850801A1 (es) * 2008-12-17 2010-07-27 Lilly Co Eli Compuestos útiles para inhibir chk1

Also Published As

Publication number Publication date
JO3145B1 (ar) 2017-09-20
KR101533166B1 (ko) 2015-07-01
AU2011326230B2 (en) 2015-02-19
TWI501956B (zh) 2015-10-01
CN103180311A (zh) 2013-06-26
PT2638033E (pt) 2015-06-01
ES2541414T3 (es) 2015-07-20
WO2012064548A1 (en) 2012-05-18
RS54012B1 (sr) 2015-10-30
US9067920B2 (en) 2015-06-30
BR112013010009A2 (pt) 2020-09-29
AR083575A1 (es) 2013-03-06
EA201390499A1 (ru) 2013-08-30
JP5792316B2 (ja) 2015-10-07
DK2638033T3 (en) 2015-04-27
KR20130099146A (ko) 2013-09-05
AU2011326230A1 (en) 2013-05-09
ME02119B (me) 2015-10-20
EP2638033A1 (en) 2013-09-18
MX2013005181A (es) 2013-10-17
SI2638033T1 (sl) 2015-05-29
EP2638033B1 (en) 2015-04-08
PL2638033T3 (pl) 2015-09-30
CA2816944C (en) 2015-12-22
CA2816944A1 (en) 2012-05-18
JP2013541586A (ja) 2013-11-14
BR112013010009B1 (pt) 2021-10-19
EA022096B1 (ru) 2015-10-30
TW201305138A (zh) 2013-02-01
US20130190262A1 (en) 2013-07-25
CN103180311B (zh) 2014-08-20

Similar Documents

Publication Publication Date Title
HRP20150530T1 (hr) Spojevi korisni za inhibiranje chk1
HRP20130167T1 (hr) Spojevi korisni za inhibiranje chk1
HRP20201681T1 (hr) Inhibitor aurora a kinaze
ME02663B (me) Derivati benzimidazola kao inhibitori pi3 kinaze
JP2013541586A5 (enExample)
NZ630205A (en) Enhancer of zeste homolog 2 inhibitors
MX2015012432A (es) Inhibidores piridinicos de la cinasa cdk9.
PH12015502628A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
BR112012027743A2 (pt) ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
WO2013004995A8 (en) Pyrimidinone compounds and their use
ME02322B (me) Kinazni inhibitor koji reguliše signalni put apoptoze
PH12018500284A1 (en) 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
CL2008001230A1 (es) Compuestos derivados de pirrol (2.3-d)pirimidina. purin-6-ilo o pirazol(3,4-d)pirimldina, inhibidores de quinasa p70 s6; composición farmaceutica; y uso para la preparación de medicamentos utiles en el tratamiento de adenocarcinomas del colon e inhibición de angiogénesis.
TN2017000511A1 (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them.
WO2009007390A3 (en) 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors
MX2014012741A (es) Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor 4 activado de proteasa (par4) para tratamiento de agregacion plaquetaria.
IL184872A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
IL185063A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
WO2012168885A3 (en) Bisacodyl and its analogues as drugs for use in the treatment of cancer
WO2013040227A3 (en) Therapeutic compounds
MX2016002795A (es) Compuestos de triazolona y usos de los mismos.